Geron Corporation
Geron Corporation (0IV3.L) Stock Overview
Explore Geron Corporation’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
846.8M
P/E Ratio
-6.30
EPS (TTM)
$-0.36
ROE
-0.48%
0IV3.L Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Geron Corporation (0IV3.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 40.14, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $4.27.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -6.30 and a market capitalization of 846.8M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Dawn Carter Bir
229
919 East Hillsdale Boulevard, Foster City, CA
2018